This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Kiacta

Celtic Pharmaceutical Holdings L.P.

Drug Names(s): Fibrillex, eprodisate disodium, NC-503

Description: Kiacta is an oral drug candidate for the treatment of AA amyloidosis through the prevention of amyloid fibril formation. Kiacta belongs to the class of glycosaminoglycan (GAG) mimetics, better know as disease-modifiers. It competes with natural GAGs for the same binding sites on the Amyloid A (AA) protein. By preventing natural GAGs from binding to the AA protein, Kiacta is expected to prevent AA fibril formation and the deposition of AA fibrils in organs.

Also, in preclinical models, Kiacta has shown an impact on metabolic changes associated with diabetes and obesity, including a significant decrease in triglyceride levels and cholesterol, a significant decrease in glycemia and an increase in insulin plasma levels.

Deal Structure: BELLUS Health (Neurochem) and Centocor
In December 2004, Neurochem announced the signing of a definitive collaboration and distribution agreement, granting Centocor (a wholly-owned subsidiary of Johnson & Johnson) exclusive distribution rights Kiacta for the prevention and treatment of AA Amyloidosis (and no other indications). The agreement includes up-front, regulatory and sales-based milestone payments valued at up to US$54 million. An escalating distribution fee will also be paid to Neurochem, the percentage of which will be based upon annual sales of Kiacta over the life of the agreement. Distribution rights granted to Centocor are worldwide, with the exception of Canada, Switzerland, China, Japan, Taiwan and South Korea which remain with Neurochem. Under the agreement, Neurochem will be responsible for product approval activities in the U.S. and E.U., as well as for global manufacturing activities. Centocor and other affiliates will manage the marketing and sales of...See full deal structure in Biomedtracker

Partners: BELLUS Health Inc.


Kiacta News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug